nodes	percent_of_prediction	percent_of_DWPC	metapath
Bexarotene—CYP2C9—Capecitabine—esophageal cancer	0.038	0.665	CbGbCtD
Bexarotene—CYP2C9—Cisplatin—esophageal cancer	0.0191	0.335	CbGbCtD
Bexarotene—Thirst—Capecitabine—esophageal cancer	0.0015	0.00309	CcSEcCtD
Bexarotene—Dermatitis bullous—Capecitabine—esophageal cancer	0.00149	0.00307	CcSEcCtD
Bexarotene—Blood uric acid increased—Methotrexate—esophageal cancer	0.00149	0.00307	CcSEcCtD
Bexarotene—Purpura—Capecitabine—esophageal cancer	0.00148	0.00305	CcSEcCtD
Bexarotene—Arthritis—Capecitabine—esophageal cancer	0.00147	0.00302	CcSEcCtD
Bexarotene—Neuropathy peripheral—Cisplatin—esophageal cancer	0.00146	0.00301	CcSEcCtD
Bexarotene—Lethargy—Capecitabine—esophageal cancer	0.00146	0.003	CcSEcCtD
Bexarotene—Cerebrovascular accident—Capecitabine—esophageal cancer	0.00146	0.003	CcSEcCtD
Bexarotene—Stomatitis—Cisplatin—esophageal cancer	0.00145	0.00299	CcSEcCtD
Bexarotene—Conjunctivitis—Cisplatin—esophageal cancer	0.00145	0.00299	CcSEcCtD
Bexarotene—Hyponatraemia—Capecitabine—esophageal cancer	0.00143	0.00295	CcSEcCtD
Bexarotene—Melaena—Methotrexate—esophageal cancer	0.00143	0.00294	CcSEcCtD
Bexarotene—Osteoarthritis—Capecitabine—esophageal cancer	0.00143	0.00294	CcSEcCtD
Bexarotene—Disturbance in sexual arousal—Capecitabine—esophageal cancer	0.00142	0.00291	CcSEcCtD
Bexarotene—Depressed level of consciousness—Methotrexate—esophageal cancer	0.00141	0.00291	CcSEcCtD
Bexarotene—Migraine—Capecitabine—esophageal cancer	0.0014	0.00289	CcSEcCtD
Bexarotene—Face oedema—Capecitabine—esophageal cancer	0.00138	0.00284	CcSEcCtD
Bexarotene—Urinary retention—Capecitabine—esophageal cancer	0.00136	0.00279	CcSEcCtD
Bexarotene—Mood swings—Capecitabine—esophageal cancer	0.00135	0.00278	CcSEcCtD
Bexarotene—Ataxia—Capecitabine—esophageal cancer	0.00134	0.00276	CcSEcCtD
Bexarotene—Blood creatinine increased—Capecitabine—esophageal cancer	0.00134	0.00275	CcSEcCtD
Bexarotene—Dehydration—Capecitabine—esophageal cancer	0.00133	0.00273	CcSEcCtD
Bexarotene—Urine output increased—Methotrexate—esophageal cancer	0.00132	0.00272	CcSEcCtD
Bexarotene—Ecchymosis—Methotrexate—esophageal cancer	0.00132	0.00272	CcSEcCtD
Bexarotene—Mouth ulceration—Methotrexate—esophageal cancer	0.00132	0.00272	CcSEcCtD
Bexarotene—Neoplasm—Methotrexate—esophageal cancer	0.00132	0.00272	CcSEcCtD
Bexarotene—Urinary tract disorder—Cisplatin—esophageal cancer	0.00132	0.00272	CcSEcCtD
Bexarotene—Liver function test abnormal—Capecitabine—esophageal cancer	0.00132	0.00271	CcSEcCtD
Bexarotene—Connective tissue disorder—Cisplatin—esophageal cancer	0.00132	0.00271	CcSEcCtD
Bexarotene—Urethral disorder—Cisplatin—esophageal cancer	0.00131	0.0027	CcSEcCtD
Bexarotene—Dry skin—Capecitabine—esophageal cancer	0.00131	0.00269	CcSEcCtD
Bexarotene—Pulmonary oedema—Methotrexate—esophageal cancer	0.0013	0.00268	CcSEcCtD
Bexarotene—Hypokalaemia—Capecitabine—esophageal cancer	0.0013	0.00267	CcSEcCtD
Bexarotene—Aspartate aminotransferase increased—Capecitabine—esophageal cancer	0.00128	0.00265	CcSEcCtD
Bexarotene—Sepsis—Methotrexate—esophageal cancer	0.00127	0.00261	CcSEcCtD
Bexarotene—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.00126	0.00259	CcSEcCtD
Bexarotene—Muscular weakness—Capecitabine—esophageal cancer	0.00126	0.00259	CcSEcCtD
Bexarotene—Eye disorder—Cisplatin—esophageal cancer	0.00125	0.00258	CcSEcCtD
Bexarotene—Tinnitus—Cisplatin—esophageal cancer	0.00125	0.00257	CcSEcCtD
Bexarotene—Lymphadenopathy—Methotrexate—esophageal cancer	0.00125	0.00256	CcSEcCtD
Bexarotene—Cardiac disorder—Cisplatin—esophageal cancer	0.00124	0.00256	CcSEcCtD
Bexarotene—Abdominal distension—Capecitabine—esophageal cancer	0.00124	0.00256	CcSEcCtD
Bexarotene—Influenza—Capecitabine—esophageal cancer	0.00123	0.00254	CcSEcCtD
Bexarotene—Dysphagia—Capecitabine—esophageal cancer	0.00123	0.00254	CcSEcCtD
Bexarotene—Polyuria—Methotrexate—esophageal cancer	0.00121	0.00249	CcSEcCtD
Bexarotene—Angina pectoris—Capecitabine—esophageal cancer	0.0012	0.00247	CcSEcCtD
Bexarotene—Arrhythmia—Cisplatin—esophageal cancer	0.0012	0.00246	CcSEcCtD
Bexarotene—Bronchitis—Capecitabine—esophageal cancer	0.00119	0.00244	CcSEcCtD
Bexarotene—Alopecia—Cisplatin—esophageal cancer	0.00118	0.00244	CcSEcCtD
Bexarotene—Hepatic failure—Methotrexate—esophageal cancer	0.00118	0.00243	CcSEcCtD
Bexarotene—Pancytopenia—Capecitabine—esophageal cancer	0.00117	0.00241	CcSEcCtD
Bexarotene—Erythema—Cisplatin—esophageal cancer	0.00117	0.0024	CcSEcCtD
Bexarotene—Malnutrition—Cisplatin—esophageal cancer	0.00117	0.0024	CcSEcCtD
Bexarotene—Neutropenia—Capecitabine—esophageal cancer	0.00115	0.00237	CcSEcCtD
Bexarotene—Dysuria—Capecitabine—esophageal cancer	0.00115	0.00237	CcSEcCtD
Bexarotene—Flatulence—Cisplatin—esophageal cancer	0.00115	0.00237	CcSEcCtD
Bexarotene—Dermatitis exfoliative—Methotrexate—esophageal cancer	0.00113	0.00232	CcSEcCtD
Bexarotene—Photosensitivity reaction—Capecitabine—esophageal cancer	0.00113	0.00232	CcSEcCtD
Bexarotene—Weight increased—Capecitabine—esophageal cancer	0.00112	0.00231	CcSEcCtD
Bexarotene—Muscle spasms—Cisplatin—esophageal cancer	0.00112	0.00231	CcSEcCtD
Bexarotene—Weight decreased—Capecitabine—esophageal cancer	0.00112	0.0023	CcSEcCtD
Bexarotene—Hyperglycaemia—Capecitabine—esophageal cancer	0.00111	0.00229	CcSEcCtD
Bexarotene—Pneumonia—Capecitabine—esophageal cancer	0.00111	0.00228	CcSEcCtD
Bexarotene—Lethargy—Methotrexate—esophageal cancer	0.00108	0.00223	CcSEcCtD
Bexarotene—Cerebrovascular accident—Methotrexate—esophageal cancer	0.00108	0.00223	CcSEcCtD
Bexarotene—Ill-defined disorder—Cisplatin—esophageal cancer	0.00108	0.00223	CcSEcCtD
Bexarotene—Neuropathy peripheral—Capecitabine—esophageal cancer	0.00108	0.00222	CcSEcCtD
Bexarotene—Anaemia—Cisplatin—esophageal cancer	0.00108	0.00222	CcSEcCtD
Bexarotene—Stomatitis—Capecitabine—esophageal cancer	0.00107	0.00221	CcSEcCtD
Bexarotene—Jaundice—Capecitabine—esophageal cancer	0.00107	0.00221	CcSEcCtD
Bexarotene—Conjunctivitis—Capecitabine—esophageal cancer	0.00107	0.0022	CcSEcCtD
Bexarotene—Urinary tract infection—Capecitabine—esophageal cancer	0.00107	0.0022	CcSEcCtD
Bexarotene—Osteoarthritis—Methotrexate—esophageal cancer	0.00106	0.00219	CcSEcCtD
Bexarotene—Malaise—Cisplatin—esophageal cancer	0.00105	0.00216	CcSEcCtD
Bexarotene—Haematuria—Capecitabine—esophageal cancer	0.00105	0.00216	CcSEcCtD
Bexarotene—Leukopenia—Cisplatin—esophageal cancer	0.00104	0.00215	CcSEcCtD
Bexarotene—Epistaxis—Capecitabine—esophageal cancer	0.00104	0.00214	CcSEcCtD
Bexarotene—Mood swings—Methotrexate—esophageal cancer	0.00101	0.00207	CcSEcCtD
Bexarotene—Ataxia—Methotrexate—esophageal cancer	0.000999	0.00206	CcSEcCtD
Bexarotene—Myalgia—Cisplatin—esophageal cancer	0.000992	0.00204	CcSEcCtD
Bexarotene—Haemoglobin—Capecitabine—esophageal cancer	0.000992	0.00204	CcSEcCtD
Bexarotene—Rhinitis—Capecitabine—esophageal cancer	0.00099	0.00204	CcSEcCtD
Bexarotene—Anxiety—Cisplatin—esophageal cancer	0.000989	0.00204	CcSEcCtD
Bexarotene—Haemorrhage—Capecitabine—esophageal cancer	0.000987	0.00203	CcSEcCtD
Bexarotene—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000986	0.00203	CcSEcCtD
Bexarotene—Hypoaesthesia—Capecitabine—esophageal cancer	0.000982	0.00202	CcSEcCtD
Bexarotene—Liver function test abnormal—Methotrexate—esophageal cancer	0.000981	0.00202	CcSEcCtD
Bexarotene—Discomfort—Cisplatin—esophageal cancer	0.000981	0.00202	CcSEcCtD
Bexarotene—Pharyngitis—Capecitabine—esophageal cancer	0.00098	0.00202	CcSEcCtD
Bexarotene—Urinary tract disorder—Capecitabine—esophageal cancer	0.000975	0.00201	CcSEcCtD
Bexarotene—Oedema peripheral—Capecitabine—esophageal cancer	0.000972	0.002	CcSEcCtD
Bexarotene—Connective tissue disorder—Capecitabine—esophageal cancer	0.00097	0.002	CcSEcCtD
Bexarotene—Urethral disorder—Capecitabine—esophageal cancer	0.000968	0.00199	CcSEcCtD
Bexarotene—Oedema—Cisplatin—esophageal cancer	0.000951	0.00196	CcSEcCtD
Bexarotene—Infection—Cisplatin—esophageal cancer	0.000945	0.00195	CcSEcCtD
Bexarotene—Nervous system disorder—Cisplatin—esophageal cancer	0.000933	0.00192	CcSEcCtD
Bexarotene—Thrombocytopenia—Cisplatin—esophageal cancer	0.000932	0.00192	CcSEcCtD
Bexarotene—Tachycardia—Cisplatin—esophageal cancer	0.000929	0.00191	CcSEcCtD
Bexarotene—Skin disorder—Cisplatin—esophageal cancer	0.000924	0.0019	CcSEcCtD
Bexarotene—Eye disorder—Capecitabine—esophageal cancer	0.000923	0.0019	CcSEcCtD
Bexarotene—Tinnitus—Capecitabine—esophageal cancer	0.00092	0.0019	CcSEcCtD
Bexarotene—Hyperhidrosis—Cisplatin—esophageal cancer	0.00092	0.00189	CcSEcCtD
Bexarotene—Cardiac disorder—Capecitabine—esophageal cancer	0.000916	0.00189	CcSEcCtD
Bexarotene—Eosinophilia—Methotrexate—esophageal cancer	0.000909	0.00187	CcSEcCtD
Bexarotene—Anorexia—Cisplatin—esophageal cancer	0.000907	0.00187	CcSEcCtD
Bexarotene—Pancreatitis—Methotrexate—esophageal cancer	0.0009	0.00185	CcSEcCtD
Bexarotene—Angiopathy—Capecitabine—esophageal cancer	0.000896	0.00184	CcSEcCtD
Bexarotene—Chills—Capecitabine—esophageal cancer	0.000886	0.00182	CcSEcCtD
Bexarotene—Arrhythmia—Capecitabine—esophageal cancer	0.000882	0.00182	CcSEcCtD
Bexarotene—Alopecia—Capecitabine—esophageal cancer	0.000872	0.0018	CcSEcCtD
Bexarotene—Pancytopenia—Methotrexate—esophageal cancer	0.000872	0.0018	CcSEcCtD
Bexarotene—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000867	0.00178	CcSEcCtD
Bexarotene—Malnutrition—Capecitabine—esophageal cancer	0.000859	0.00177	CcSEcCtD
Bexarotene—Erythema—Capecitabine—esophageal cancer	0.000859	0.00177	CcSEcCtD
Bexarotene—Neutropenia—Methotrexate—esophageal cancer	0.000858	0.00177	CcSEcCtD
Bexarotene—Dysuria—Methotrexate—esophageal cancer	0.000858	0.00177	CcSEcCtD
Bexarotene—Paraesthesia—Cisplatin—esophageal cancer	0.000854	0.00176	CcSEcCtD
Bexarotene—Dyspnoea—Cisplatin—esophageal cancer	0.000848	0.00175	CcSEcCtD
Bexarotene—Flatulence—Capecitabine—esophageal cancer	0.000847	0.00174	CcSEcCtD
Bexarotene—Erectile dysfunction—Methotrexate—esophageal cancer	0.000846	0.00174	CcSEcCtD
Bexarotene—Dysgeusia—Capecitabine—esophageal cancer	0.000842	0.00173	CcSEcCtD
Bexarotene—Photosensitivity reaction—Methotrexate—esophageal cancer	0.000838	0.00173	CcSEcCtD
Bexarotene—Back pain—Capecitabine—esophageal cancer	0.000831	0.00171	CcSEcCtD
Bexarotene—Decreased appetite—Cisplatin—esophageal cancer	0.000827	0.0017	CcSEcCtD
Bexarotene—Muscle spasms—Capecitabine—esophageal cancer	0.000826	0.0017	CcSEcCtD
Bexarotene—Pneumonia—Methotrexate—esophageal cancer	0.000823	0.0017	CcSEcCtD
Bexarotene—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000821	0.00169	CcSEcCtD
Bexarotene—Pain—Cisplatin—esophageal cancer	0.000814	0.00168	CcSEcCtD
Bexarotene—Stomatitis—Methotrexate—esophageal cancer	0.000798	0.00164	CcSEcCtD
Bexarotene—Ill-defined disorder—Capecitabine—esophageal cancer	0.000797	0.00164	CcSEcCtD
Bexarotene—Conjunctivitis—Methotrexate—esophageal cancer	0.000796	0.00164	CcSEcCtD
Bexarotene—Anaemia—Capecitabine—esophageal cancer	0.000794	0.00164	CcSEcCtD
Bexarotene—Sweating—Methotrexate—esophageal cancer	0.000785	0.00162	CcSEcCtD
Bexarotene—Feeling abnormal—Cisplatin—esophageal cancer	0.000784	0.00161	CcSEcCtD
Bexarotene—Haematuria—Methotrexate—esophageal cancer	0.000781	0.00161	CcSEcCtD
Bexarotene—Malaise—Capecitabine—esophageal cancer	0.000775	0.0016	CcSEcCtD
Bexarotene—Epistaxis—Methotrexate—esophageal cancer	0.000772	0.00159	CcSEcCtD
Bexarotene—Vertigo—Capecitabine—esophageal cancer	0.000772	0.00159	CcSEcCtD
Bexarotene—Syncope—Capecitabine—esophageal cancer	0.000771	0.00159	CcSEcCtD
Bexarotene—Leukopenia—Capecitabine—esophageal cancer	0.000769	0.00158	CcSEcCtD
Bexarotene—Palpitations—Capecitabine—esophageal cancer	0.000759	0.00156	CcSEcCtD
Bexarotene—Loss of consciousness—Capecitabine—esophageal cancer	0.000755	0.00156	CcSEcCtD
Bexarotene—Body temperature increased—Cisplatin—esophageal cancer	0.000752	0.00155	CcSEcCtD
Bexarotene—Cough—Capecitabine—esophageal cancer	0.00075	0.00154	CcSEcCtD
Bexarotene—Hypertension—Capecitabine—esophageal cancer	0.000742	0.00153	CcSEcCtD
Bexarotene—Haemoglobin—Methotrexate—esophageal cancer	0.000739	0.00152	CcSEcCtD
Bexarotene—Haemorrhage—Methotrexate—esophageal cancer	0.000735	0.00151	CcSEcCtD
Bexarotene—Myalgia—Capecitabine—esophageal cancer	0.000732	0.00151	CcSEcCtD
Bexarotene—Arthralgia—Capecitabine—esophageal cancer	0.000732	0.00151	CcSEcCtD
Bexarotene—Chest pain—Capecitabine—esophageal cancer	0.000732	0.00151	CcSEcCtD
Bexarotene—Pharyngitis—Methotrexate—esophageal cancer	0.000729	0.0015	CcSEcCtD
Bexarotene—Anxiety—Capecitabine—esophageal cancer	0.000729	0.0015	CcSEcCtD
Bexarotene—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000727	0.0015	CcSEcCtD
Bexarotene—Urinary tract disorder—Methotrexate—esophageal cancer	0.000726	0.00149	CcSEcCtD
Bexarotene—Discomfort—Capecitabine—esophageal cancer	0.000723	0.00149	CcSEcCtD
Bexarotene—Urethral disorder—Methotrexate—esophageal cancer	0.00072	0.00148	CcSEcCtD
Bexarotene—Dry mouth—Capecitabine—esophageal cancer	0.000715	0.00147	CcSEcCtD
Bexarotene—Confusional state—Capecitabine—esophageal cancer	0.000707	0.00146	CcSEcCtD
Bexarotene—Oedema—Capecitabine—esophageal cancer	0.000701	0.00144	CcSEcCtD
Bexarotene—Hypersensitivity—Cisplatin—esophageal cancer	0.000701	0.00144	CcSEcCtD
Bexarotene—Infection—Capecitabine—esophageal cancer	0.000697	0.00143	CcSEcCtD
Bexarotene—Shock—Capecitabine—esophageal cancer	0.00069	0.00142	CcSEcCtD
Bexarotene—Nervous system disorder—Capecitabine—esophageal cancer	0.000688	0.00142	CcSEcCtD
Bexarotene—Eye disorder—Methotrexate—esophageal cancer	0.000687	0.00141	CcSEcCtD
Bexarotene—Thrombocytopenia—Capecitabine—esophageal cancer	0.000687	0.00141	CcSEcCtD
Bexarotene—Tinnitus—Methotrexate—esophageal cancer	0.000685	0.00141	CcSEcCtD
Bexarotene—Tachycardia—Capecitabine—esophageal cancer	0.000684	0.00141	CcSEcCtD
Bexarotene—Asthenia—Cisplatin—esophageal cancer	0.000683	0.00141	CcSEcCtD
Bexarotene—Cardiac disorder—Methotrexate—esophageal cancer	0.000682	0.0014	CcSEcCtD
Bexarotene—Skin disorder—Capecitabine—esophageal cancer	0.000681	0.0014	CcSEcCtD
Bexarotene—Hyperhidrosis—Capecitabine—esophageal cancer	0.000678	0.0014	CcSEcCtD
Bexarotene—Anorexia—Capecitabine—esophageal cancer	0.000669	0.00138	CcSEcCtD
Bexarotene—Angiopathy—Methotrexate—esophageal cancer	0.000667	0.00137	CcSEcCtD
Bexarotene—Chills—Methotrexate—esophageal cancer	0.000659	0.00136	CcSEcCtD
Bexarotene—Diarrhoea—Cisplatin—esophageal cancer	0.000651	0.00134	CcSEcCtD
Bexarotene—Alopecia—Methotrexate—esophageal cancer	0.000649	0.00134	CcSEcCtD
Bexarotene—Erythema—Methotrexate—esophageal cancer	0.00064	0.00132	CcSEcCtD
Bexarotene—Malnutrition—Methotrexate—esophageal cancer	0.00064	0.00132	CcSEcCtD
Bexarotene—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000639	0.00132	CcSEcCtD
Bexarotene—Insomnia—Capecitabine—esophageal cancer	0.000634	0.00131	CcSEcCtD
Bexarotene—Paraesthesia—Capecitabine—esophageal cancer	0.00063	0.0013	CcSEcCtD
Bexarotene—Dysgeusia—Methotrexate—esophageal cancer	0.000626	0.00129	CcSEcCtD
Bexarotene—Dyspnoea—Capecitabine—esophageal cancer	0.000625	0.00129	CcSEcCtD
Bexarotene—Back pain—Methotrexate—esophageal cancer	0.000619	0.00127	CcSEcCtD
Bexarotene—Dyspepsia—Capecitabine—esophageal cancer	0.000617	0.00127	CcSEcCtD
Bexarotene—Decreased appetite—Capecitabine—esophageal cancer	0.00061	0.00126	CcSEcCtD
Bexarotene—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000605	0.00125	CcSEcCtD
Bexarotene—Vomiting—Cisplatin—esophageal cancer	0.000605	0.00125	CcSEcCtD
Bexarotene—Fatigue—Capecitabine—esophageal cancer	0.000605	0.00124	CcSEcCtD
Bexarotene—Rash—Cisplatin—esophageal cancer	0.0006	0.00124	CcSEcCtD
Bexarotene—Constipation—Capecitabine—esophageal cancer	0.0006	0.00123	CcSEcCtD
Bexarotene—Pain—Capecitabine—esophageal cancer	0.0006	0.00123	CcSEcCtD
Bexarotene—Dermatitis—Cisplatin—esophageal cancer	0.000599	0.00123	CcSEcCtD
Bexarotene—Ill-defined disorder—Methotrexate—esophageal cancer	0.000594	0.00122	CcSEcCtD
Bexarotene—RXRA—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CREBBP—esophageal cancer	0.000592	0.00129	CbGpPWpGaD
Bexarotene—Anaemia—Methotrexate—esophageal cancer	0.000591	0.00122	CcSEcCtD
Bexarotene—RXRG—Generic Transcription Pathway—SMAD4—esophageal cancer	0.00059	0.00129	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—SMAD4—esophageal cancer	0.000582	0.00127	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—ABCB1—esophageal cancer	0.000582	0.00127	CbGpPWpGaD
Bexarotene—Feeling abnormal—Capecitabine—esophageal cancer	0.000578	0.00119	CcSEcCtD
Bexarotene—Malaise—Methotrexate—esophageal cancer	0.000577	0.00119	CcSEcCtD
Bexarotene—Vertigo—Methotrexate—esophageal cancer	0.000575	0.00118	CcSEcCtD
Bexarotene—RXRA—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	0.000575	0.00126	CbGpPWpGaD
Bexarotene—RXRA—Transmembrane transport of small molecules—ATP4A—esophageal cancer	0.000575	0.00126	CbGpPWpGaD
Bexarotene—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000573	0.00118	CcSEcCtD
Bexarotene—Leukopenia—Methotrexate—esophageal cancer	0.000573	0.00118	CcSEcCtD
Bexarotene—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—esophageal cancer	0.00057	0.00125	CbGpPWpGaD
Bexarotene—Nausea—Cisplatin—esophageal cancer	0.000565	0.00116	CcSEcCtD
Bexarotene—RXRB—Gene Expression—NR1I2—esophageal cancer	0.000565	0.00124	CbGpPWpGaD
Bexarotene—Cough—Methotrexate—esophageal cancer	0.000558	0.00115	CcSEcCtD
Bexarotene—RXRB—Generic Transcription Pathway—SMAD4—esophageal cancer	0.000555	0.00121	CbGpPWpGaD
Bexarotene—Body temperature increased—Capecitabine—esophageal cancer	0.000554	0.00114	CcSEcCtD
Bexarotene—Abdominal pain—Capecitabine—esophageal cancer	0.000554	0.00114	CcSEcCtD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—BAX—esophageal cancer	0.000551	0.0012	CbGpPWpGaD
Bexarotene—RXRA—Transcriptional regulation of white adipocyte differentiation—EP300—esophageal cancer	0.000548	0.0012	CbGpPWpGaD
Bexarotene—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A6—esophageal cancer	0.000545	0.00119	CbGpPWpGaD
Bexarotene—Arthralgia—Methotrexate—esophageal cancer	0.000545	0.00112	CcSEcCtD
Bexarotene—Chest pain—Methotrexate—esophageal cancer	0.000545	0.00112	CcSEcCtD
Bexarotene—Myalgia—Methotrexate—esophageal cancer	0.000545	0.00112	CcSEcCtD
Bexarotene—CYP3A4—Tryptophan metabolism—CYP1B1—esophageal cancer	0.000544	0.00119	CbGpPWpGaD
Bexarotene—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000541	0.00111	CcSEcCtD
Bexarotene—CYP2C9—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.00054	0.00118	CbGpPWpGaD
Bexarotene—CYP3A4—Oxidation by Cytochrome P450—CYP2A6—esophageal cancer	0.000538	0.00118	CbGpPWpGaD
Bexarotene—Discomfort—Methotrexate—esophageal cancer	0.000538	0.00111	CcSEcCtD
Bexarotene—CYP2C9—Biological oxidations—ADH1B—esophageal cancer	0.000537	0.00118	CbGpPWpGaD
Bexarotene—RXRA—Adipogenesis—RB1—esophageal cancer	0.000527	0.00115	CbGpPWpGaD
Bexarotene—Confusional state—Methotrexate—esophageal cancer	0.000526	0.00108	CcSEcCtD
Bexarotene—Infection—Methotrexate—esophageal cancer	0.000519	0.00107	CcSEcCtD
Bexarotene—Hypersensitivity—Capecitabine—esophageal cancer	0.000517	0.00106	CcSEcCtD
Bexarotene—RXRG—Gene Expression—HIST1H2BM—esophageal cancer	0.000515	0.00113	CbGpPWpGaD
Bexarotene—Nervous system disorder—Methotrexate—esophageal cancer	0.000512	0.00105	CcSEcCtD
Bexarotene—Thrombocytopenia—Methotrexate—esophageal cancer	0.000511	0.00105	CcSEcCtD
Bexarotene—CYP3A4—Tryptophan metabolism—CYP19A1—esophageal cancer	0.000511	0.00112	CbGpPWpGaD
Bexarotene—CYP2C9—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.000508	0.00111	CbGpPWpGaD
Bexarotene—Skin disorder—Methotrexate—esophageal cancer	0.000507	0.00104	CcSEcCtD
Bexarotene—Hyperhidrosis—Methotrexate—esophageal cancer	0.000505	0.00104	CcSEcCtD
Bexarotene—Asthenia—Capecitabine—esophageal cancer	0.000503	0.00104	CcSEcCtD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	0.000501	0.0011	CbGpPWpGaD
Bexarotene—CYP2C9—Biological oxidations—CYP26A1—esophageal cancer	0.0005	0.00109	CbGpPWpGaD
Bexarotene—Anorexia—Methotrexate—esophageal cancer	0.000498	0.00102	CcSEcCtD
Bexarotene—Pruritus—Capecitabine—esophageal cancer	0.000496	0.00102	CcSEcCtD
Bexarotene—RXRA—Developmental Biology—CFL1—esophageal cancer	0.000494	0.00108	CbGpPWpGaD
Bexarotene—CYP2C9—Metapathway biotransformation—CYP26A1—esophageal cancer	0.000493	0.00108	CbGpPWpGaD
Bexarotene—RXRA—Organelle biogenesis and maintenance—CREBBP—esophageal cancer	0.000485	0.00106	CbGpPWpGaD
Bexarotene—RXRB—Gene Expression—HIST1H2BM—esophageal cancer	0.000485	0.00106	CbGpPWpGaD
Bexarotene—Diarrhoea—Capecitabine—esophageal cancer	0.00048	0.000988	CcSEcCtD
Bexarotene—RXRA—Developmental Biology—SOX2—esophageal cancer	0.000477	0.00104	CbGpPWpGaD
Bexarotene—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000476	0.000979	CcSEcCtD
Bexarotene—Insomnia—Methotrexate—esophageal cancer	0.000472	0.000972	CcSEcCtD
Bexarotene—CYP3A4—Phase 1 - Functionalization of compounds—ALDH2—esophageal cancer	0.00047	0.00103	CbGpPWpGaD
Bexarotene—Paraesthesia—Methotrexate—esophageal cancer	0.000469	0.000965	CcSEcCtD
Bexarotene—Dyspnoea—Methotrexate—esophageal cancer	0.000465	0.000958	CcSEcCtD
Bexarotene—CYP2C9—Biological oxidations—GSTO1—esophageal cancer	0.000465	0.00102	CbGpPWpGaD
Bexarotene—Somnolence—Methotrexate—esophageal cancer	0.000464	0.000956	CcSEcCtD
Bexarotene—Dizziness—Capecitabine—esophageal cancer	0.000464	0.000955	CcSEcCtD
Bexarotene—Dyspepsia—Methotrexate—esophageal cancer	0.00046	0.000946	CcSEcCtD
Bexarotene—CYP2C9—Metapathway biotransformation—GSTO1—esophageal cancer	0.000458	0.001	CbGpPWpGaD
Bexarotene—Decreased appetite—Methotrexate—esophageal cancer	0.000454	0.000934	CcSEcCtD
Bexarotene—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000451	0.000928	CcSEcCtD
Bexarotene—Fatigue—Methotrexate—esophageal cancer	0.00045	0.000927	CcSEcCtD
Bexarotene—Pain—Methotrexate—esophageal cancer	0.000446	0.000919	CcSEcCtD
Bexarotene—Vomiting—Capecitabine—esophageal cancer	0.000446	0.000918	CcSEcCtD
Bexarotene—Rash—Capecitabine—esophageal cancer	0.000442	0.00091	CcSEcCtD
Bexarotene—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A6—esophageal cancer	0.000442	0.000967	CbGpPWpGaD
Bexarotene—Dermatitis—Capecitabine—esophageal cancer	0.000442	0.00091	CcSEcCtD
Bexarotene—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—esophageal cancer	0.00044	0.000961	CbGpPWpGaD
Bexarotene—Headache—Capecitabine—esophageal cancer	0.000439	0.000905	CcSEcCtD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	0.000437	0.000956	CbGpPWpGaD
Bexarotene—RXRA—Transmembrane transport of small molecules—ABCC2—esophageal cancer	0.000436	0.000953	CbGpPWpGaD
Bexarotene—RXRG—Generic Transcription Pathway—NOTCH1—esophageal cancer	0.000435	0.000951	CbGpPWpGaD
Bexarotene—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—esophageal cancer	0.000434	0.000949	CbGpPWpGaD
Bexarotene—Feeling abnormal—Methotrexate—esophageal cancer	0.00043	0.000886	CcSEcCtD
Bexarotene—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000427	0.000879	CcSEcCtD
Bexarotene—RXRA—Developmental Biology—ACTB—esophageal cancer	0.00042	0.000918	CbGpPWpGaD
Bexarotene—CYP3A4—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	0.000419	0.000916	CbGpPWpGaD
Bexarotene—Nausea—Capecitabine—esophageal cancer	0.000417	0.000858	CcSEcCtD
Bexarotene—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	0.000413	0.000904	CbGpPWpGaD
Bexarotene—Abdominal pain—Methotrexate—esophageal cancer	0.000413	0.00085	CcSEcCtD
Bexarotene—Body temperature increased—Methotrexate—esophageal cancer	0.000413	0.00085	CcSEcCtD
Bexarotene—RXRA—Developmental Biology—CTNNA1—esophageal cancer	0.000412	0.000902	CbGpPWpGaD
Bexarotene—RXRA—PPARA activates gene expression—EP300—esophageal cancer	0.000412	0.000901	CbGpPWpGaD
Bexarotene—RXRB—Generic Transcription Pathway—NOTCH1—esophageal cancer	0.000409	0.000895	CbGpPWpGaD
Bexarotene—RXRA—Fatty acid, triacylglycerol, and ketone body metabolism—CREBBP—esophageal cancer	0.000408	0.000892	CbGpPWpGaD
Bexarotene—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.000408	0.000892	CbGpPWpGaD
Bexarotene—CYP3A4—Biological oxidations—ADH7—esophageal cancer	0.000404	0.000884	CbGpPWpGaD
Bexarotene—RXRA—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—esophageal cancer	0.000403	0.000882	CbGpPWpGaD
Bexarotene—RXRG—Gene Expression—PSME1—esophageal cancer	0.0004	0.000874	CbGpPWpGaD
Bexarotene—RXRG—Gene Expression—PSME2—esophageal cancer	0.0004	0.000874	CbGpPWpGaD
Bexarotene—RXRA—Transmembrane transport of small molecules—GNG7—esophageal cancer	0.000395	0.000864	CbGpPWpGaD
Bexarotene—RXRG—Generic Transcription Pathway—CREBBP—esophageal cancer	0.000394	0.000863	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—CASP8—esophageal cancer	0.000391	0.000855	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—CREBBP—esophageal cancer	0.000389	0.000851	CbGpPWpGaD
Bexarotene—RXRA—Gene Expression—SMG6—esophageal cancer	0.000388	0.000849	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—BLVRB—esophageal cancer	0.000388	0.000849	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—SLC52A3—esophageal cancer	0.000388	0.000849	CbGpPWpGaD
Bexarotene—Hypersensitivity—Methotrexate—esophageal cancer	0.000385	0.000792	CcSEcCtD
Bexarotene—RXRA—Generic Transcription Pathway—NOTCH3—esophageal cancer	0.000384	0.00084	CbGpPWpGaD
Bexarotene—RXRA—Adipogenesis—CDKN1A—esophageal cancer	0.000379	0.000829	CbGpPWpGaD
Bexarotene—CYP2C9—Biological oxidations—ALDH2—esophageal cancer	0.000379	0.000828	CbGpPWpGaD
Bexarotene—RXRG—Gene Expression—NOTCH3—esophageal cancer	0.000377	0.000825	CbGpPWpGaD
Bexarotene—RXRB—Gene Expression—PSME1—esophageal cancer	0.000376	0.000822	CbGpPWpGaD
Bexarotene—RXRB—Gene Expression—PSME2—esophageal cancer	0.000376	0.000822	CbGpPWpGaD
Bexarotene—Asthenia—Methotrexate—esophageal cancer	0.000375	0.000771	CcSEcCtD
Bexarotene—RXRB—Generic Transcription Pathway—CREBBP—esophageal cancer	0.000371	0.000811	CbGpPWpGaD
Bexarotene—Pruritus—Methotrexate—esophageal cancer	0.000369	0.000761	CcSEcCtD
Bexarotene—CYP2C9—Biological oxidations—GSTT1—esophageal cancer	0.00036	0.000788	CbGpPWpGaD
Bexarotene—Diarrhoea—Methotrexate—esophageal cancer	0.000357	0.000735	CcSEcCtD
Bexarotene—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.000356	0.000779	CbGpPWpGaD
Bexarotene—CYP2C9—Biological oxidations—CYP2A6—esophageal cancer	0.000356	0.000779	CbGpPWpGaD
Bexarotene—RXRB—Gene Expression—NOTCH3—esophageal cancer	0.000355	0.000776	CbGpPWpGaD
Bexarotene—CYP3A4—Biological oxidations—ADH1B—esophageal cancer	0.000354	0.000775	CbGpPWpGaD
Bexarotene—CYP2C9—Arachidonic acid metabolism—PTGS2—esophageal cancer	0.000348	0.00076	CbGpPWpGaD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	0.000347	0.000759	CbGpPWpGaD
Bexarotene—Dizziness—Methotrexate—esophageal cancer	0.000345	0.000711	CcSEcCtD
Bexarotene—RXRA—Generic Transcription Pathway—NOTCH2—esophageal cancer	0.000344	0.000753	CbGpPWpGaD
Bexarotene—RXRG—Gene Expression—NOTCH2—esophageal cancer	0.000338	0.00074	CbGpPWpGaD
Bexarotene—CYP2C9—Biological oxidations—PTGS1—esophageal cancer	0.000338	0.000738	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—BCL2—esophageal cancer	0.000335	0.000733	CbGpPWpGaD
Bexarotene—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.000335	0.000733	CbGpPWpGaD
Bexarotene—Vomiting—Methotrexate—esophageal cancer	0.000332	0.000683	CcSEcCtD
Bexarotene—RXRA—Metabolism—SLC10A2—esophageal cancer	0.00033	0.000722	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—CA1—esophageal cancer	0.00033	0.000722	CbGpPWpGaD
Bexarotene—CYP3A4—Biological oxidations—CYP26A1—esophageal cancer	0.00033	0.000721	CbGpPWpGaD
Bexarotene—Rash—Methotrexate—esophageal cancer	0.000329	0.000678	CcSEcCtD
Bexarotene—Dermatitis—Methotrexate—esophageal cancer	0.000329	0.000677	CcSEcCtD
Bexarotene—Headache—Methotrexate—esophageal cancer	0.000327	0.000673	CcSEcCtD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—ERBB2—esophageal cancer	0.000326	0.000713	CbGpPWpGaD
Bexarotene—CYP3A4—Metapathway biotransformation—CYP26A1—esophageal cancer	0.000325	0.000711	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—PTGS2—esophageal cancer	0.000319	0.000697	CbGpPWpGaD
Bexarotene—RXRB—Gene Expression—NOTCH2—esophageal cancer	0.000318	0.000696	CbGpPWpGaD
Bexarotene—Nausea—Methotrexate—esophageal cancer	0.00031	0.000639	CcSEcCtD
Bexarotene—CYP3A4—Biological oxidations—GSTO1—esophageal cancer	0.000306	0.00067	CbGpPWpGaD
Bexarotene—CYP3A4—Metapathway biotransformation—GSTO1—esophageal cancer	0.000302	0.000661	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—CA2—esophageal cancer	0.000302	0.000661	CbGpPWpGaD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	0.000295	0.000646	CbGpPWpGaD
Bexarotene—RXRA—Gene Expression—NR1I2—esophageal cancer	0.000294	0.000644	CbGpPWpGaD
Bexarotene—RXRA—Generic Transcription Pathway—SMAD4—esophageal cancer	0.000289	0.000632	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—CCND1—esophageal cancer	0.000288	0.00063	CbGpPWpGaD
Bexarotene—CYP2C9—Biological oxidations—CYP1B1—esophageal cancer	0.000287	0.000628	CbGpPWpGaD
Bexarotene—RXRG—Gene Expression—SMAD4—esophageal cancer	0.000284	0.000621	CbGpPWpGaD
Bexarotene—CYP2C9—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000283	0.000619	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—ABL1—esophageal cancer	0.000281	0.000615	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—ADH7—esophageal cancer	0.000281	0.000614	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—PLCE1—esophageal cancer	0.000281	0.000614	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—CDKN1A—esophageal cancer	0.000278	0.000609	CbGpPWpGaD
Bexarotene—RXRA—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—esophageal cancer	0.000278	0.000608	CbGpPWpGaD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	0.000278	0.000607	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	0.000277	0.000605	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—SMAD4—esophageal cancer	0.000272	0.000595	CbGpPWpGaD
Bexarotene—CYP2C9—Biological oxidations—CYP19A1—esophageal cancer	0.00027	0.00059	CbGpPWpGaD
Bexarotene—RXRB—Gene Expression—SMAD4—esophageal cancer	0.000267	0.000584	CbGpPWpGaD
Bexarotene—CYP2C9—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000266	0.000582	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—EP300—esophageal cancer	0.000265	0.00058	CbGpPWpGaD
Bexarotene—RXRA—Gene Expression—HIST1H2BM—esophageal cancer	0.000253	0.000552	CbGpPWpGaD
Bexarotene—CYP3A4—Biological oxidations—ALDH2—esophageal cancer	0.00025	0.000546	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—ADH1B—esophageal cancer	0.000246	0.000538	CbGpPWpGaD
Bexarotene—RXRA—Transmembrane transport of small molecules—HMOX1—esophageal cancer	0.000241	0.000527	CbGpPWpGaD
Bexarotene—CYP3A4—Biological oxidations—GSTT1—esophageal cancer	0.000238	0.00052	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—TYMP—esophageal cancer	0.000235	0.000515	CbGpPWpGaD
Bexarotene—CYP3A4—Biological oxidations—CYP2A6—esophageal cancer	0.000235	0.000514	CbGpPWpGaD
Bexarotene—RXRG—Generic Transcription Pathway—MYC—esophageal cancer	0.000234	0.000512	CbGpPWpGaD
Bexarotene—RXRA—Transmembrane transport of small molecules—ABCB1—esophageal cancer	0.000231	0.000506	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	0.000231	0.000505	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—CYP26A1—esophageal cancer	0.000229	0.000501	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	0.000226	0.000494	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—ALOX15—esophageal cancer	0.000223	0.000488	CbGpPWpGaD
Bexarotene—CYP3A4—Biological oxidations—PTGS1—esophageal cancer	0.000223	0.000487	CbGpPWpGaD
Bexarotene—RXRB—Generic Transcription Pathway—MYC—esophageal cancer	0.00022	0.000481	CbGpPWpGaD
Bexarotene—RXRA—Generic Transcription Pathway—NOTCH1—esophageal cancer	0.000213	0.000466	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—KDR—esophageal cancer	0.000213	0.000466	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—GSTO1—esophageal cancer	0.000213	0.000465	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—TPI1—esophageal cancer	0.000213	0.000465	CbGpPWpGaD
Bexarotene—RXRG—Gene Expression—NOTCH1—esophageal cancer	0.000209	0.000458	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—MET—esophageal cancer	0.000208	0.000456	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—ALDOB—esophageal cancer	0.000204	0.000446	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—NOTCH1—esophageal cancer	0.000201	0.000439	CbGpPWpGaD
Bexarotene—RXRB—Gene Expression—NOTCH1—esophageal cancer	0.000197	0.000431	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—GAPDH—esophageal cancer	0.000196	0.000429	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	0.000196	0.000429	CbGpPWpGaD
Bexarotene—RXRA—Gene Expression—PSME1—esophageal cancer	0.000196	0.000429	CbGpPWpGaD
Bexarotene—RXRA—Gene Expression—PSME2—esophageal cancer	0.000196	0.000429	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—CRABP1—esophageal cancer	0.000195	0.000426	CbGpPWpGaD
Bexarotene—RXRA—Generic Transcription Pathway—CREBBP—esophageal cancer	0.000193	0.000423	CbGpPWpGaD
Bexarotene—RXRG—Gene Expression—CREBBP—esophageal cancer	0.00019	0.000415	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	0.00019	0.000415	CbGpPWpGaD
Bexarotene—CYP3A4—Biological oxidations—CYP1B1—esophageal cancer	0.000189	0.000414	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	0.000187	0.000409	CbGpPWpGaD
Bexarotene—CYP3A4—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000187	0.000408	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—GNG7—esophageal cancer	0.000185	0.000405	CbGpPWpGaD
Bexarotene—RXRA—Gene Expression—NOTCH3—esophageal cancer	0.000185	0.000404	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—CREBBP—esophageal cancer	0.000182	0.000398	CbGpPWpGaD
Bexarotene—RXRB—Gene Expression—CREBBP—esophageal cancer	0.000179	0.00039	CbGpPWpGaD
Bexarotene—CYP3A4—Biological oxidations—CYP19A1—esophageal cancer	0.000178	0.000389	CbGpPWpGaD
Bexarotene—CYP3A4—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000176	0.000384	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—ALDH2—esophageal cancer	0.000173	0.000379	CbGpPWpGaD
Bexarotene—RXRA—Gene Expression—NOTCH2—esophageal cancer	0.000166	0.000363	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—GSTT1—esophageal cancer	0.000165	0.000361	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	0.000163	0.000357	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—CYP2A6—esophageal cancer	0.000163	0.000357	CbGpPWpGaD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	0.000162	0.000355	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—ENO1—esophageal cancer	0.000155	0.000338	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—PTGS1—esophageal cancer	0.000155	0.000338	CbGpPWpGaD
Bexarotene—RXRA—Transmembrane transport of small molecules—CREBBP—esophageal cancer	0.000154	0.000338	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—PSME2—esophageal cancer	0.000152	0.000333	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—PSME1—esophageal cancer	0.000152	0.000333	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—ERBB2—esophageal cancer	0.000152	0.000333	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—BLVRB—esophageal cancer	0.000145	0.000317	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—SLC52A3—esophageal cancer	0.000145	0.000317	CbGpPWpGaD
Bexarotene—RXRA—Gene Expression—SMAD4—esophageal cancer	0.000139	0.000304	CbGpPWpGaD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	0.000133	0.000291	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—CYP1B1—esophageal cancer	0.000131	0.000288	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	0.00013	0.000283	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—EP300—esophageal cancer	0.000124	0.000271	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—CYP19A1—esophageal cancer	0.000124	0.00027	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—CA1—esophageal cancer	0.000123	0.00027	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—SLC10A2—esophageal cancer	0.000123	0.00027	CbGpPWpGaD
Bexarotene—RXRA—Generic Transcription Pathway—MYC—esophageal cancer	0.000115	0.000251	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—HMOX1—esophageal cancer	0.000113	0.000247	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—CA2—esophageal cancer	0.000113	0.000247	CbGpPWpGaD
Bexarotene—RXRG—Gene Expression—MYC—esophageal cancer	0.000113	0.000246	CbGpPWpGaD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	0.000111	0.000242	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	0.00011	0.000241	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—ABCB1—esophageal cancer	0.000108	0.000237	CbGpPWpGaD
Bexarotene—RXRB—Gene Expression—MYC—esophageal cancer	0.000106	0.000232	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—EGFR—esophageal cancer	0.000106	0.000231	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—ADH7—esophageal cancer	0.000105	0.000229	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—PLCE1—esophageal cancer	0.000105	0.000229	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	0.000104	0.000227	CbGpPWpGaD
Bexarotene—RXRA—Gene Expression—NOTCH1—esophageal cancer	0.000103	0.000224	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—BLVRB—esophageal cancer	9.56e-05	0.000209	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—SLC52A3—esophageal cancer	9.56e-05	0.000209	CbGpPWpGaD
Bexarotene—RXRA—Gene Expression—CREBBP—esophageal cancer	9.3e-05	0.000204	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—ADH1B—esophageal cancer	9.19e-05	0.000201	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—TYMP—esophageal cancer	8.78e-05	0.000192	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—CYP26A1—esophageal cancer	8.54e-05	0.000187	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—ALOX15—esophageal cancer	8.33e-05	0.000182	CbGpPWpGaD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	8.18e-05	0.000179	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—SLC10A2—esophageal cancer	8.13e-05	0.000178	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—CA1—esophageal cancer	8.13e-05	0.000178	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—TPI1—esophageal cancer	7.94e-05	0.000174	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—GSTO1—esophageal cancer	7.94e-05	0.000174	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—ALDOB—esophageal cancer	7.62e-05	0.000167	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—CA2—esophageal cancer	7.44e-05	0.000163	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—GAPDH—esophageal cancer	7.33e-05	0.00016	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—CRABP1—esophageal cancer	7.27e-05	0.000159	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—CREBBP—esophageal cancer	7.23e-05	0.000158	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—PLCE1—esophageal cancer	6.91e-05	0.000151	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—ADH7—esophageal cancer	6.91e-05	0.000151	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—GNG7—esophageal cancer	6.91e-05	0.000151	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—NOS3—esophageal cancer	6.48e-05	0.000142	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—ALDH2—esophageal cancer	6.48e-05	0.000142	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—GSTT1—esophageal cancer	6.16e-05	0.000135	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—CYP2A6—esophageal cancer	6.09e-05	0.000133	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	6.07e-05	0.000133	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—ADH1B—esophageal cancer	6.06e-05	0.000133	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—PTGS2—esophageal cancer	5.92e-05	0.00013	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—TYMP—esophageal cancer	5.79e-05	0.000127	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—ENO1—esophageal cancer	5.77e-05	0.000126	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—PTGS1—esophageal cancer	5.77e-05	0.000126	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—PSME1—esophageal cancer	5.69e-05	0.000124	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—PSME2—esophageal cancer	5.69e-05	0.000124	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—CYP26A1—esophageal cancer	5.64e-05	0.000123	CbGpPWpGaD
Bexarotene—RXRA—Gene Expression—MYC—esophageal cancer	5.52e-05	0.000121	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—ALOX15—esophageal cancer	5.49e-05	0.00012	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—GSTO1—esophageal cancer	5.24e-05	0.000115	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—TPI1—esophageal cancer	5.24e-05	0.000115	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—ALDOB—esophageal cancer	5.02e-05	0.00011	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	4.97e-05	0.000109	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—EP300—esophageal cancer	4.93e-05	0.000108	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—CYP1B1—esophageal cancer	4.91e-05	0.000107	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—GAPDH—esophageal cancer	4.83e-05	0.000106	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—CRABP1—esophageal cancer	4.79e-05	0.000105	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—CYP19A1—esophageal cancer	4.61e-05	0.000101	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—GNG7—esophageal cancer	4.56e-05	9.97e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—ALDH2—esophageal cancer	4.27e-05	9.34e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—HMOX1—esophageal cancer	4.21e-05	9.21e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	4.13e-05	9.03e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—GSTT1—esophageal cancer	4.06e-05	8.88e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—ABCB1—esophageal cancer	4.04e-05	8.84e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—CYP2A6—esophageal cancer	4.02e-05	8.78e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—PTGS1—esophageal cancer	3.81e-05	8.33e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—ENO1—esophageal cancer	3.81e-05	8.33e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—PSME1—esophageal cancer	3.75e-05	8.2e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—PSME2—esophageal cancer	3.75e-05	8.2e-05	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—PIK3CA—esophageal cancer	3.65e-05	7.97e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—CYP1B1—esophageal cancer	3.24e-05	7.08e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	3.06e-05	6.68e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—CYP19A1—esophageal cancer	3.04e-05	6.66e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—HMOX1—esophageal cancer	2.78e-05	6.07e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—CREBBP—esophageal cancer	2.7e-05	5.91e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—ABCB1—esophageal cancer	2.67e-05	5.83e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—NOS3—esophageal cancer	2.42e-05	5.29e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—PTGS2—esophageal cancer	2.21e-05	4.84e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—EP300—esophageal cancer	1.84e-05	4.02e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—CREBBP—esophageal cancer	1.78e-05	3.9e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—NOS3—esophageal cancer	1.59e-05	3.49e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—PTGS2—esophageal cancer	1.46e-05	3.19e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—PIK3CA—esophageal cancer	1.36e-05	2.98e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—EP300—esophageal cancer	1.21e-05	2.65e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—PIK3CA—esophageal cancer	8.97e-06	1.96e-05	CbGpPWpGaD
